Clinical Trials Logo

Esophageal Adenocarcinoma clinical trials

View clinical trials related to Esophageal Adenocarcinoma.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT03604991 Suspended - Clinical trials for Gastroesophageal Junction Adenocarcinoma

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Start date: May 3, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. Immunotherapy with antibodies, such as nivolumab and ipilimumab, may remove the brake on the body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy and radiation therapy may reduce the tumor size and the amount of normal tissue that needs to be removed during surgery. A combined treatment with nivolumab and ipilimumab, chemotherapy, and radiation therapy might be more effective in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery.

NCT ID: NCT03366012 Suspended - Barrett Esophagus Clinical Trials

Rapid Assessment of Esophageal Adenocarcinoma Risk Test

REACT
Start date: August 1, 2018
Phase: N/A
Study type: Interventional

This study aims to evaluate the acceptability of a new non-invasive screening device to test for Barrett's esophagus. The investigators will prospectively enroll 100 patients to undergo Cytosponge testing. The time of involvement for an individual will range from 2 weeks to 2 months, depending on the results of the Cytosponge test and time to follow up endoscopy, if indicated.